Global Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Region: Trend Forecast and Growth Opportunity

Global biodefense market will reach $15.85 billion by 2030, growing by 6.2% annually over 2020-2030 owing to the rising need for military and civilian vaccines and equipment against diseases including COVID-19 pandemic. Biodefense is a set medical or military measures that are taken in response to restoring biosecurity of a country against biological toxins or infectious agents that can be used with an intent to kill or infect humans, animals, or the environment and to instigate biological warfare. Agents used for bioterrorism can be living organisms, such as bacteria, viruses, fungi, and toxins. These agents can be used deliberately to infect humans and to kill them to create social and economic turmoil. Factors such as favorable government initiatives in the U.S., growing investment from private players, increased government focus and funding towards biodefense strategies, and growing prevalence of various agents such as the Ebola Virus, Zika Virus, and Flu, are driving the market for biodefense. The development of genetic engineering and biotechnology over the past few decades has made it simple to change these harmful and naturally existing viruses, which can now be modified to do much more harm. Furthermore, it is simple to access these organisms, making biodefense an essential component for nations all over the world. Anthrax, botulism, and chemical and radioactive agents are examples of biological agents that have been employed as a vehicle for bioterrorism in the past and caused severe economic devastation. These occurrences compelled the creation of biodefense laws, agreements, and regulations by the government in order to defend against biological threats, lower risks, and prepare for, respond to, and recover from bio-incidents. The National Institute of Infectious Disease has played a crucial role in developing medical products and strategies to counter bioterrorism and emerging and re-emerging infectious diseases by conducting ongoing research to diagnose, treat, and prevent them, whether they are intentional or naturally occurring, since the anthrax bioterrorism act that was carried out in 2001 through mail. Governments of many countries have been collaborating with several international partners to support response activities and increase preparedness. For instance, an experimental single-dose Ebola vaccine manufactured by Merck [rVSV-ZEBOV-GP] has been authorized under safe use by the World Health Organization and DRC MoH. The North American region is expected to showcase a significant CAGR over the forecast period. This is attributed to the presence of high federal funding, technological advancements, and growing awareness among the population. The presence of major players in this region is also a favourable prospect for the market. National Biodefense Strategy is aligned with the 2018 National Security Strategy of the United States. The strategy is to detect and contain biothreats at their source, support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. The market for biodefense in the Asia-Pacific region is also being driven by the expanding significance of biodefense and the rising threat of dangerous biological materials that cause emergencies. As a result of the availability of established facilities for the production of vaccines in these nations, Australia and Japan are two of the region's most established marketplaces for biodefense. Furthermore, the country's market position is aided by the sophisticated healthcare infrastructure present there. To prepare for future biological dangers, nations like China and India are aggressively enhancing their R&D capacities. After the United States, China spends the second-highest proportion of its GDP on research and development. These are the elements that are anticipated to increase the biodefense market in the area.

COVID-19 Impact 

Emergence of life threatening diseases such as Nipah and Coronavirus and COVID-19 variants and mutations have led to robust increase in multidisciplinary actions by governments to prevent future outbreaks, and this is expected to fuel revenue growth of the global biodefense market over the forecast period. The Delta variant surfaced in the U.S., and was first identified in India in late 2020, and infected numerous individuals in the U.K. as well. Until mid-December 2020, it remained the predominant SARS COV-2 variant, accounting for over 99% of COVID-19 cases (at the time) and leading to an overwhelming increase in hospitalizations in some states. Omicron is currently the predominant variant in the U.S. According to studies, Omicron is proving to be less severe than Delta in all age groups, and even in adults older than 65 and in children too young to be vaccinated. Governments in countries across the globe are engaged in drafting policy initiatives and strategy plans pertaining to biodefense and biosecurity, and this has opened-up significant growth opportunities for emerging pharmaceutical companies operating in this market.

Highlighted with 84 tables and 73 figures, this 165-page report “Global Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. 

In-depth qualitative analyses include identification and investigation of the following aspects:
   • Market Structure 
   • Growth Drivers 
   • Restraints and Challenges
   • Emerging Product Trends & Market Opportunities
   • Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Region. 

By Product type  
     • Vaccines
            • Anthrax
            • Smallpox
            • Botulism
            • Nuclear/Radiation
            • E-Bola
            • Zika
            • Other Vaccines
     • Biothreat Detection Devices
            • Detectors/Triggering Devices
            • Assays and Reagents
            • Samplers
            • Identifiers
     •Antibiotics
     • Masks
     • Other Products 

By Sales Channel
     • Online Sales
     • Offline Sales

By Application
     • Military
     • Civilian

By Geography
     • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
     • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
     • North America (U.S., Canada, and Mexico)
     • South America (Brazil, Chile, Argentina, Rest of South America)
     • Rest of World  (Saudi Arabia, UAE, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product, Sales Channel, Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 
Achaogen, Inc., Alexeter Technologies LLC, Alnylam Pharmaceuticals, Inc., Altimmune, Inc., Bavarian Nordic AS, BioFactura, Inc., Cleveland Biolabs, Inc., Dynavax Technologies Inc, Dynport Vaccine Company LLC (DVC), Elusys Therapeutics, Inc., Emergent BioSolutions Inc, General Dynamics Corp., GlaxoSmithKline Plc, Ichor Medical Systems, Mediimmune (AstraZeneca), Nanotherapeutics, Inc., Ology Bioscience, PathSensors Inc, Pluristem Therapeutics, Sanofi Pasteur Ltd., SIGA Technologies, Inc., Soligenix, Inc., Xoma Corporation, 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now